Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $17.33
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have earned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month […]
More Stories
TotalEnergies SE (NYSE:TTE) Receives $80.00 Consensus Target Price from Analysts
TotalEnergies SE (NYSE:TTE – Get Free Report) has earned an average rating of “Hold” from the seven analysts that are...
LifeStance Health Group, Inc. (NASDAQ:LFST) Given Average Rating of “Hold” by Analysts
Shares of LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) have been given an average recommendation of “Hold” by...
Vast Renewables (NASDAQ:VSTE) & Babcock & Wilcox Enterprises (NYSE:BW) Head-To-Head Analysis
Vast Renewables (NASDAQ:VSTE – Get Free Report) and Babcock & Wilcox Enterprises (NYSE:BW – Get Free Report) are both small-cap...
Gossamer Bio (NASDAQ:GOSS) vs. Northwest Biotherapeutics (OTCMKTS:NWBO) Critical Analysis
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) and Gossamer Bio (NASDAQ:GOSS – Get Free Report) are both small-cap medical companies,...
Analyzing Gold Royalty (GROY) and The Competition
Gold Royalty (NYSE:GROY – Get Free Report) is one of 111 publicly-traded companies in the “Gold & silver ores” industry,...
Financial Analysis: Air Industries Group (NYSE:AIRI) vs. Loar (NYSE:LOAR)
Loar (NYSE:LOAR – Get Free Report) and Air Industries Group (NYSE:AIRI – Get Free Report) are both aerospace companies, but...